Kalceks
Kalceks is a Latvian pharmaceutical company founded in 1920 that develops and manufactures sterile injectable and hospital medicines — covering cardiovascular, oncology supportive care, anesthetics, antibiotics, and CNS therapies — for distribution through pharmaceutical wholesalers to hospitals across 77 countries.
- Company typePrivate
- Founded1920
- HeadquartersRiga, Latvia
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kalceks does
Kalceks is a Latvian pharmaceutical manufacturer founded in 1920 in Riga, specializing in sterile dosage forms and parenteral medicines for the hospital segment. Its portfolio spans cardiovascular, oncology supportive care, anesthetics and analgesics (including myorelaxants), sterile antibiotics, alimentary and metabolism, blood-related, central nervous system, musculoskeletal, ophthalmic, and controlled emergency medicines. Manufacturing is conducted through parent Grindeks Group's facilities in Latvia and Slovakia, supplemented by European contract manufacturers, with strict GMP, ISO 14001, and EU Falsified Medicines Directive compliance (data matrix codes on prescription products since 2019).
The company operates a wholesale-mediated B2B model, selling to pharmaceutical wholesalers that in turn supply hospitals and healthcare institutions across 77 countries, with roughly 60% of exports directed to European markets. Kalceks joined the Grindeks holding group in 2004 and has since pursued active export market development, including direct entry into Germany in 2019 and a long-term distribution partnership with Austria-based EVER Pharma in October 2022 covering five products in cardiology, CNS, and oncology supportive care. The product portfolio was supplemented with seven new generics in 2021 and 42 medicines were reported as under development in 2022, with 16 product registrations secured in Germany and an additional 8 planned.
Revenue is generated through one-time B2B product sales of generic and branded hospital pharmaceuticals; pricing is not publicly disclosed. The company is privately held as a Latvian joint-stock company (akciju sabiedrība "Kalceks"), with no public listing, no disclosed funding rounds, and a headcount of 51-100. Customer-facing engagement is digital-light, relying on a multilingual website, LinkedIn/Facebook presence, and email newsletter, with commercial activity concentrated on direct relationships with pharmaceutical wholesalers and healthcare professionals.
Kalceks firmographics
Firmographics- Name
- Kalceks
- Legal name
- akciju sabiedrība "Kalceks"
- Website
- https://kalceks.lv
- Company type
- Private
- Founded year
- 1920
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Kalceks is a Latvian pharmaceutical company founded in 1920 that develops and manufactures sterile injectable and hospital medicines — covering cardiovascular, oncology supportive care, anesthetics, antibiotics, and CNS therapies — for distribution through pharmaceutical wholesalers to hospitals across 77 countries.
- Ownership category
- akta.pro rank
Kalceks industry classification
Industry- Product category
- Hospital Pharmaceuticals (Sterile Injectables and Generic Medicines)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
Keywords
Where Kalceks is headquartered
LocationHeadquarters
- HQ city
- Riga
- HQ country
- Latvia
- HQ region
- Europe
Offices1 record
Markets served
Kalceks business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Sale of generic/hospital pharmaceuticals to wholesalers and healthcare institutions. Products include sterile medicines, controlled medications, anesthetics, myorelaxants, cardiovascular drugs, antibiotics, and oncology products.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Kalceks product offering
Product offeringCore offering
Kalceks develops and manufactures generic and specialty pharmaceuticals for the hospital segment, with a focus on sterile dosage forms, parenteral medicines, and injectable solutions. Its portfolio spans cardiovascular, oncology supportive care, anesthetics/analgesics, antibiotics, nervous system, and other therapeutic areas, and is sold to pharmaceutical wholesalers that distribute to hospitals in 77 countries.
Product overview
Kalceks is a pharmaceutical company specializing in hospital segment medications and sterile dosage forms. The product portfolio includes injectable solutions, controlled medicines for resuscitation, CNS, and cardiovascular therapy, organized into therapeutic categories: cardiovascular system, antineoplastics (oncology supportive care), anesthetics and analgesics (including myorelaxants), antibiotics, alimentary tract and metabolism, blood products, nervous system, musculoskeletal system, and eye drops. The company develops and manufactures both generic and proprietary medicines, with production within the Grindeks Group in Latvia and Slovakia, as well as in other contract manufacturing facilities across Europe. Products are exported to 77 countries worldwide with 60% going to European countries.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Products available in 77 countries worldwide
- +1 more outcomes
Companies that use Kalceks
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Kalceks technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Kalceks partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- EVER PharmacoreLong-term distribution partnership in Germany covering five products in cardiology, central nervous system, and oncology supportive care therapeutic areas. This partnership nearly doubled the number of Kalceks products marketed in Germany. EVER Pharma is an Austrian-based fully integrated pharmaceutical company founded in 1934, focused on neurology and specialty injectables. Products available in over 70 countries worldwide.
Scale indicators5 records
Recent moves9 records
Expansion highlights5 records
Kalceks competitors and assessment
Company assessmentBroad incumbents
- Sandoz (Novartis): World's largest generics manufacturer, with a leading portfolio of hospital sterile injectables across antibiotics, anesthetics, and oncology. Represents the competitive ceiling for hospital injectable generics.
- Fresenius Kabi: Global leader in generic injectable pharmaceuticals, IV drugs, and clinical nutrition for hospitals. Comparable as a major hospital injectables incumbent with overlapping anesthesia, ICU, and oncology supportive care lines.
- B. Braun: German medical technology and pharmaceutical company offering IV solutions, injectables, and infusion therapy for hospitals. Overlaps with Kalceks in sterile parenteral products and hospital distribution.
- STADA Arzneimittel: European-focused generic pharmaceutical company with strong hospital injectables portfolio, particularly in Germany and Eastern Europe. Directly competes with Kalceks in Central and Eastern European hospital tenders.
Regional players
- KRKA: Slovenian-headquartered generic pharmaceutical manufacturer with strong Central and Eastern European distribution and a growing hospital injectables portfolio. Comparable as a CEE regional generic pharma peer.
- Polpharma: Polish generic pharmaceutical company with a broad hospital and prescription generics portfolio across Central and Eastern Europe. Comparable as a CEE regional player in similar therapeutic categories.
Emerging players
- Aurobindo Pharma: India-based generic injectable manufacturer with growing European presence, particularly in hospital antibiotics and sterile injectables. Comparable as a lower-cost emerging player with hospital injectable focus.
Direct peers
- EVER Pharma: Austrian-headquartered specialty injectables and neurology pharmaceutical company with products in over 70 countries. Directly comparable as a hospital-segment injectable generics manufacturer and existing distribution partner of Kalceks.
- Hikma Pharmaceuticals: Specialty generics manufacturer with a strong hospital injectables business across the US, Europe, and MENA. Comparable in therapeutic focus areas including anesthesia, oncology, and cardiovascular injectables.
- Sintetica: Switzerland-based sterile injectable generics manufacturer focused on hospital anesthesia, analgesics, and emergency medicines across European and international markets. Closely matches Kalceks' product categories and B2B hospital focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Kalceks social profiles
Digital presenceKalceks compliance and trust
Trust signalCompliance4 records
Kalceks financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kalceks leadership team
Management profileNumber of profiles
Profiles9 records
Kalceks funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kalceks M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kalceks
What does Kalceks do?
Kalceks develops and manufactures generic and specialty pharmaceuticals for the hospital segment, with a focus on sterile dosage forms, parenteral medicines, and injectable solutions. Its portfolio spans cardiovascular, oncology supportive care, anesthetics/analgesics, antibiotics, nervous system, and other therapeutic areas, and is sold to pharmaceutical wholesalers that distribute to hospitals in 77 countries.
Is Kalceks a public or private company?
Kalceks is a private company. It is classified as corporate owned and is currently operating.
When was Kalceks founded?
Kalceks was founded in 1920. It employs 51 to 100 people.
Where is Kalceks based?
Kalceks is headquartered in Riga, Latvia, in the Europe region.
How does Kalceks make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Kalceks's main competitors?
Broad incumbents on record are Sandoz (Novartis), Fresenius Kabi, B. Braun and STADA Arzneimittel. Regional players are KRKA and Polpharma. Aurobindo Pharma is listed as an emerging player. Direct peers are EVER Pharma, Hikma Pharmaceuticals and Sintetica.
Does Kalceks have an API?
No public API is recorded for Kalceks.
What industry is Kalceks in?
Kalceks's product category is Hospital Pharmaceuticals (Sterile Injectables and Generic Medicines). Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.